Fame and Mortality: Evidence from a Retrospective Analysis of Singers
November 26, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
N/A
Synonyms :
pumecitinib
Class :
JAK inhibitor
Brand Name :
N/A
Synonyms :
pumecitinib
Class :
JAK inhibitor
Dosage forms and strengths
It is an investigational drug
The drug is a JAK inhibitor which is studied for its anti-inflammatory properties
It is an investigational drug
The drug is a JAK inhibitor which is studied for its anti-inflammatory properties
It is an investigational drug
The drug is a JAK inhibitor which is studied for its anti-inflammatory properties
It is an investigational drug
The drug is a JAK inhibitor which is studied for its anti-inflammatory properties
Not indicated
Refer adult dosing
Action and spectrum
Action
Pumecitinib blocks JAK enzymes, crucial for immune signaling. It targets JAK1 and JAK3, reducing inflammation and immune cell activation.
Frequency not defined
None
Black Box Warning:
None
Contraindications:
Hypersenstivity: Allergic reactions to pumecitinib or its components must avoid its use.
Pregnancy and Breastfeeding: Pumecitinib isn’t recommended during pregnancy unless benefits outweigh risks, and it’s advised against during breastfeeding due lack of data for excretion into breast milk.
Severe liver conditions: Pumecitinib are contraindicated due to the potential worsening of hepatic conditions.
Pregnancy category: N/A
Lactation: Excreted into human milk is unknown
Pregnancy Categories:
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus in either the first or second trimester.
<b>Category B: There were a lack of studies on pregnant women and no evidence of risk to the fetus in animal experiments.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Pharmacology:
Pumecitinib, a potent and selective inhibitor, primarily focuses on specific signaling pathways crucial in diverse physiological processes.
Pharmacodynamics:
Pumecitinib works by blocking protein kinases, particularly JAK1 and JAK2, which control signaling pathways related to inflammation, immunity, and blood cell production.
Pharmacokinetics:
Limited information available
Administration:
The healthcare provider decides the dosage and schedule based on factors like the patient’s condition, medical history, and other medications they are taking.
Patient information leaflet
Generic Name: pumecitinib
Why do we use pumecitinib?
Pumecitinib benefits adults with severe rheumatoid arthritis who haven’t responded to other treatments.
It’s also used for psoriatic arthritis to reduce joint inflammation and manage pain, swelling, and skin issues in patients who didn’t respond to previous treatments.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
